According to a new report from Intel Market Research, global scleral lens market was valued at USD 331 million in 2024 and is projected to reach USD 975 million by 2032, growing at a robust CAGR of 16.8% during the forecast period (2025–2032). This growth is driven by increasing prevalence of corneal disorders, technological advancements in lens design, and growing adoption of non-surgical vision correction solutions.
What are Scleral Lenses?
Scleral lenses are specialized large-diameter gas-permeable contact lenses that rest on the sclera (white of the eye) and create a fluid-filled vault over the cornea. These medical devices, ranging from 14.5mm to 24mm in diameter, serve as ocular surface prostheses for patients with corneal irregularities and severe dry eye conditions. Unlike conventional contact lenses, scleral lenses don’t touch the cornea, making them ideal for therapeutic applications where traditional lenses fail.
Mini-scleral lenses dominate the product segment with approximately 75% market share, while eye clinics account for nearly 70% of application use. These lenses have become the gold standard for managing conditions like keratoconus, post-surgical complications, and severe ocular surface diseases where other vision correction methods prove inadequate.
📥 Download Sample Report: https://www.intelmarketresearch.com/download-free-sample/989/scleral-lens-2025-2032-839
Key Market Drivers
1. Rising Prevalence of Ocular Disorders
The global burden of refractive vision disorders has created substantial demand for advanced corneal correction solutions. Conditions like keratoconus, which affects approximately 1 in 2,000 people worldwide, often prove resistant to conventional contact lenses or glasses. Scleral lenses have emerged as an effective therapeutic option, with clinical studies showing over 85% visual improvement in keratoconus patients. The growing geriatric population—projected to reach 1.5 billion by 2030—further exacerbates age-related vision problems, creating sustained market demand.
2. Technological Advancements in Lens Materials and Design
Recent breakthroughs in gas-permeable materials and digital fitting technologies have transformed scleral lens performance. Modern lenses now offer oxygen permeability levels exceeding 150 Dk, addressing previous concerns about corneal oxygenation. Computerized corneal topographers allow for precise mapping of irregular corneas, enabling customized lens fitting with success rates improving from 65% to over 90% in recent years. The development of hybrid materials combining rigidity for optical correction with peripheral flexibility for comfort has significantly expanded wearability.
Leading manufacturers have introduced next-generation scleral lenses with proprietary surface treatments that reduce protein deposits by nearly 40% compared to conventional designs. These innovations have dramatically improved patient comfort and extended wearing times, making scleral lenses a more viable long-term solution for complex vision correction needs.
Market Challenges
- High cost and complex fitting process: The average cost of a single scleral lens ranges between $1,500-$2,500, nearly 8-10 times more expensive than standard contact lenses, while the fitting process requires multiple specialized appointments averaging 3-5 visits
- Limited practitioner expertise: Only about 15% of eye care professionals currently possess specialized training in scleral lens fitting, creating geographic disparities in access
- Regulatory complexities: Classification of these devices varies significantly across regions, creating compliance challenges for manufacturers operating globally
Opportunities Ahead
The scleral lens market presents significant growth opportunities through expansion in emerging markets and development of pediatric applications. The Asia-Pacific region is projected to grow at a CAGR of over 18% through 2032, outpacing global averages. Rising disposable incomes in countries like China and India, combined with increasing awareness about advanced vision correction, create favorable conditions for market expansion.
Recent clinical evidence demonstrating scleral lenses’ effectiveness in pediatric cases of congenital cataracts and ocular trauma has opened new therapeutic avenues. Over 70% of pediatric ophthalmologists now consider scleral lenses a viable alternative to corneal transplants in select cases. Additionally, the industry is witnessing transformative changes in service delivery through telemedicine-enabled fitting consultations, which have reduced geographic barriers by 40% in pilot programs.
📥 Download Sample PDF: https://www.intelmarketresearch.com/download-free-sample/989/scleral-lens-2025-2032-839
Regional Market Insights
- North America: Leads global market share with approximately 45% of global revenue, driven by advanced healthcare infrastructure, high awareness, and robust insurance coverage for specialty lenses
- Europe: Characterized by rigorous medical device regulations under EU MDR 2017/745, with countries like Germany and the U.K. leading in adoption due to well-established optometry networks
- Asia-Pacific: Fastest-growing region propelled by rising awareness, growing disposable incomes, and improved eye-care access, particularly in Japan and Australia
- Latin America and Middle East & Africa: Emerging markets showing promising growth through medical tourism, improving healthcare infrastructure, and increasing prevalence of dry eye conditions
Market Segmentation
By Type
- Mini-Scleral Lenses (14.5mm-18mm)
- Large-Scleral Lenses (18mm-24mm)
By Application
- Therapeutic
- Refractive
- Cosmetic
By Indication
- Keratoconus
- Dry Eye Syndrome
- Corneal Ectasia
- Post-Surgical Rehabilitation
- Other Ocular Surface Disorders
By Distribution Channel
- Direct-to-Consumer
- Online Platforms
- Specialty Clinics & Optometrists
- Lens Manufacturers’ Distributors
📘 Get Full Report: https://www.intelmarketresearch.com/life-sciences/989/scleral-lens-2025-2032-839
Competitive Landscape
The global scleral lens market features a semi-consolidated structure with established medical device companies competing alongside specialized ophthalmic manufacturers. ABB Optical Group and Bausch Health Companies Inc. collectively dominate over 35% of market share, leveraging their comprehensive product portfolios and extensive distribution networks across North America and Europe.
The report provides in-depth competitive profiling of key players, including:
- ABB Optical Group
- Bausch Health Companies Inc.
- CooperVision
- EssilorLuxottica
- BostonSight
- Art Optical Contact Lens Inc.
- Visionary Optics
- AccuLens Inc.
- Menicon Co., Ltd
Recent Industry Developments
The scleral lens market has witnessed significant recent advancements, including:
May 2024: Bausch + Lomb launched Zenlens ECHO, a custom, non-prosthetic scleral contact lens designed for a wide range of corneal anatomies, featuring enhanced customization capabilities without requiring additional training or equipment.
February 2025: ABB Optical Group launched its DELTA Scleral, a next-generation scleral contact lens designed for intuitive fitting using a delta-from-baseline adjustment method to simplify chair time and precision.
October 2023: BostonSight partnered with Moorfields Eye Hospital NHS in the UK to manufacture and distribute its SCLERAL lenses domestically, including comprehensive education initiatives for optometrists and patients.
Report Deliverables
- Global and regional market forecasts from 2025 to 2032
- Strategic insights into technological developments, clinical trials, and regulatory approvals
- Market share analysis and SWOT assessments
- Pricing trends and reimbursement dynamics
- Comprehensive segmentation by type, application, indication, and geography
📘 Get Full Report: https://www.intelmarketresearch.com/life-sciences/989/scleral-lens-2025-2032-839
📥 Download Sample PDF: https://www.intelmarketresearch.com/download-free-sample/989/scleral-lens-2025-2032-839
About Intel Market Research
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:
- Real-time competitive benchmarking
- Global clinical trial pipeline monitoring
- Country-specific regulatory and pricing analysis
- Over 500+ healthcare reports annually
Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.
🌐 Website: https://www.intelmarketresearch.com 📞 Asia-Pacific: +91 9169164321 🔗 LinkedIn: Follow Us
